Blood-based test can predict risk of developing symptoms of Alzheimer's up to a decade early
medicalxpress - A blood test for the biomarker phosphorylated tau 217 (p-tau217) recently received federal clearance, but questions have emerged about the extent to which such tests can accurately predict whether a cognitively healthy individual will develop cognitive im…
AI Summary: Researchers validated a blood‑based test that flags individuals at elevated risk of developing Alzheimer’s symptoms up to a decade earlier, showing strong predictive accuracy across cohorts. The finding could enable earlier monitoring and trial enrollment, but raises questions about screening protocols, follow‑up care and the psychological burden of long‑lead risk information.
- Blood biomarkers forecast Alzheimer's risk years ahead (4)
- Genetics and clearance mechanisms shaping Alzheimer's onset (3)
- Sleep, frailty and resilience as non-blood early signals (3)
Blood biomarkers forecast Alzheimer's risk years ahead
Genetics and clearance mechanisms shaping Alzheimer's onset
Sleep, frailty and resilience as non-blood early signals
CVS Caremark, FTC settle insulin pricing case for $13B
Ella Jeffries / beckershospitalreview - The Federal Trade Commission reached a settlement with CVS Caremark that requires the pharmacy benefit manager to change its business practices as part of the agency’s antitrust case alleging the PBM inflated insulin list prices through rebate practices. …
AI Summary: CVS Caremark agreed to a $13 billion settlement with the Federal Trade Commission to resolve allegations tied to its handling of insulin pricing and related business practices. The deal includes a large cash payment and operational changes designed to address the FTC’s concerns, and now awaits court approval and implementation details.